中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

485 records (took 0.045 seconds)

    Methods of screening embryonic progenitor cell lines
    42.
    发明授权
    Methods of screening embryonic progenitor cell lines 有权

    公开(公告)号：US10920191B2

    公开(公告)日：2021-02-16

    申请号：US15846181

    申请日：2017-12-18

    Applicant: LINEAGE CELL THERAPEUTICS, INC.

    Inventor： Michael West ,  Hal Sternberg ,  Karen Chapman

    IPC: C12N5/00 ,  C12N5/02 ,  C12N5/0735 ,  C12N5/077

    Abstract: Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion. The robustness of these clonally-purified lines, their ability to expand for >40 passages while maintaining their pattern of gene expression, lack of tumorigenicity, and their embryonic pattern of gene expression offers novel compositions and methods for modeling numerous differentiation pathways for the first time in vitro, and for the manufacture of purified product not existing in such a purified state in nature or using other manufacturing modalities. Representative progenitor cell lines described herein are capable of development into cutaneous adipocytes, blood-brain barrier cells, neuronal cells, or smooth muscle cells each with therapeutic potential.

    Hydroxyl-containing compounds
    46.
    发明申请
    Hydroxyl-containing compounds 审中-公开
    含羟基化合物

    公开(公告)号：US20030207901A1

    公开(公告)日：2003-11-06

    申请号：US10437298

    申请日：2003-05-14

    Applicant: Cell Therapeutics, Inc.

    Inventor： Gail E. Underiner ,  David Porubek ,  J. Peter Klein ,  Paul Woodson ,  Stephen J. Klaus ,  Anil M. Kumar ,  John Tulinsky

    IPC: A61K031/525 ,  A61K031/522 ,  A61K031/517 ,  A61K031/47 ,  A61K031/4035

    CPC classification number: A61K31/47 ,  A61K31/4035 ,  A61K31/517 ,  A61K31/522 ,  A61K31/525

    Abstract: Disclosed are therapeutic compounds having the formula: (R)j-(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: 1 n is an integer from 1 to 20, at least one of X or Y is nullOH. Another of X or Y, which is not nullOH, is hydrogen, CH3null, CH3nullCH2null, CH3null(CH2)2null or (CH3)2nullCH2null, and each W1, W2, and W3 is independently hydrogen, CH3null, CH3nullCH2null, CH3null(CH2)2null or (CH3)2nullCH2null. The X, Y, W1, W2, or W3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

    Abstract translation: 公开了具有下式的治疗化合物：（R）j-（CORE MOIETY），包括拆分的对映异构体，非对映体，水合物，盐，溶剂合物及其混合物。 j是1至3的整数，核心部分是具有至少一个含有5至6个环原子和至多2个氮杂原子的杂环的双环结构。 R选自氢，卤素，羟基，氨基，取代或未取代的苄基，C 1-6烷基或C 1-6烯基，至少一个R具有式I：n为1至20的整数， X或Y中的至少一个是-OH。 不是-OH的X或Y中的另一个是氢，CH 3 - ，CH 3 -CH 2 - ，CH 3 - （CH 2）2 - 或（CH 3）2 -CH 2 - ，并且每个W 1，W 2和W 3独立地是氢 ，CH 3 - ，CH 3 -CH 2 - ，CH 3 - （CH 2）2 - 或（CH 3）2 -CH 2 - 。 X，Y，W1，W2或W3烷基可以是未取代的或被羟基，卤素或二甲基氨基取代。 所公开的化合物及其治疗组合物可用于治疗由第二信使活性介导的患有疾病或治疗诱导的毒性的个体。

    Effect of growth hormone and IGF-1 on neural stem cells
    47.
    发明申请
    Effect of growth hormone and IGF-1 on neural stem cells 审中-公开
    生长激素和IGF-1对神经干细胞的影响

    公开(公告)号：US20030054551A1

    公开(公告)日：2003-03-20

    申请号：US10231492

    申请日：2002-08-30

    Applicant: Stem Cell Therapeutics Inc.

    Inventor： Tetsuro Shingo ,  Samuel Weiss

    IPC: A61K038/18 ,  C12N005/08 ,  A61K038/27 ,  A61K038/30 ,  A61K031/56 ,  A61K031/7076 ,  A61K031/405

    CPC classification number: C12N5/0623 ,  A61K35/12 ,  A61K38/1816 ,  A61K38/2257 ,  A61K38/27 ,  A61K38/30 ,  A61K2300/00

    Abstract: The present invention provides a method of increasing neural stem cell numbers by using growth hormone and/or IGF-1. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions.

    Abstract translation: 本发明提供了通过使用生长激素和/或IGF-1增加神经干细胞数量的方法。 该方法可以在体内实施以获得更多的原位神经干细胞，其又可产生更多的神经元或神经胶质细胞以补偿丢失或功能失调的神经细胞。 该方法也可以在体外实施以在培养物中产生大量的神经干细胞。 培养的干细胞可用于例如患有神经变性疾病或病症的患者或动物的移植治疗。

    Mammalian CDP-diacylglycerol synthase
    49.
    发明申请
    Mammalian CDP-diacylglycerol synthase 审中-公开
    哺乳动物CDP-二酰基甘油合酶

    公开(公告)号：US20020168747A1

    公开(公告)日：2002-11-14

    申请号：US10136517

    申请日：2002-05-02

    Applicant: CELL THERAPEUTICS, INC.

    Inventor： David W. Leung

    IPC: C12N009/20 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

    CPC classification number: C12N9/1241 ,  C12Y207/07041

    Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylyltransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid metabolism and signaling in mammalian cells, in particular, the production of purified forms of CDS.

    Abstract translation: 公开了具有酶CDP-二酰基甘油合成酶（CDS）活性的cDNA序列和多肽。 CDS也称为CTP：磷脂酰胞苷酰转移酶。 进一步公开了分离和产生参与哺乳动物细胞中磷脂酸代谢和信号传导的多肽的方法，特别是生产纯化形式的CDS。

Patent Agency Ranking